China smartphone shipments slumped in June on inventory overhang: Jefferies
Adicet Bio, Inc., a pharmaceutical company currently valued at $43 million in market capitalization, has been notified by the Nasdaq Stock Market that it is not in compliance with the minimum bid price requirement for continued listing. This development came to light following a notification received by the company on Monday, April 7, 2025, which stated that the closing bid price of Adicet Bio’s common stock had been below $1.00 per share for 30 consecutive business days. According to InvestingPro data, the stock currently trades at $0.54, representing an 80% decline over the past year.
The company’s stock, traded under the ticker (NASDAQ:ACET), is still actively listed on the Nasdaq Global Market. To address the issue, Adicet Bio has been given a grace period of 180 calendar days, until October 6, 2025, to regain compliance with Nasdaq’s Bid Price Rule. During this period, the company must achieve a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. InvestingPro analysis indicates the stock is currently in oversold territory, with the price hovering near its 52-week low of $0.45.
Nasdaq has the discretion to extend the requirement up to 20 consecutive business days. Should Adicet Bio fail to meet the requirement by the Compliance Date, it may be granted an additional 180 days if it meets certain conditions, including a possible reverse stock split to increase the per-share price.
The company has expressed its intention to closely monitor its stock’s closing bid price and to explore all feasible options to meet the Nasdaq’s requirements and maintain its listing. While there is no guarantee that Adicet Bio will achieve compliance or remain in line with other Nasdaq criteria, the company maintains a strong liquidity position with a current ratio of 9.29 and holds more cash than debt on its balance sheet. For deeper insights into Adicet Bio’s financial health and 15 additional key ProTips, visit InvestingPro.
This situation underscores the challenges faced by companies in the biotech sector, where stock performance can be volatile and influenced by various factors, including regulatory approvals and market reception of pharmaceutical products. With analysts maintaining coverage and two recently revising their earnings estimates upward for the upcoming period, Adicet Bio’s future steps towards compliance will be closely watched by investors and market analysts.
This report is based on a statement from an SEC filing.
In other recent news, Adicet Bio, Inc. has been actively progressing with its clinical trials and regulatory designations. The company has received Fast Track Designation from the FDA for its investigational therapy, ADI-001, aimed at treating systemic sclerosis and other autoimmune diseases, including lupus nephritis and systemic lupus erythematosus. This designation is intended to accelerate the development and review of drugs addressing serious conditions with unmet medical needs. The Phase 1 clinical trial for ADI-001 in lupus nephritis has enrolled three patients since November 2024, with preliminary results expected in the first half of 2025. Adicet Bio plans to expand enrollment for additional autoimmune conditions, such as systemic sclerosis and idiopathic inflammatory myopathy, starting in the second quarter of 2025. Analyst firm H.C. Wainwright has maintained a Neutral rating on Adicet Bio, noting the company’s progress with ADI-001. The company also reported that its ADI-270 program for renal cell carcinoma has enrolled three patients, with preliminary data anticipated in the first half of 2025. These developments highlight Adicet Bio’s ongoing efforts to advance its pipeline of therapies for cancer and autoimmune diseases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.